Navigation Links
SyntheMed, Inc. Announces Stockholder Approval of Planned Merger With Pathfinder, LLC
Date:8/25/2011

RINGWOOD, N.J., Aug. 25, 2011 /PRNewswire/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD; Pink Sheets: SYMD) announced that its stockholders approved the planned merger with Pathfinder, LLC at SyntheMed's special meeting of stockholders held today.  In excess of 99% of the votes cast were voted in favor of the merger.  The proposed merger with Pathfinder was previously announced and is described in detail in SyntheMed's definitive proxy statement filed with the Securities and Exchange Commission on July 26, 2011.  The merger has been approved by Pathfinder's members and is expected to close in the next ten days, subject to satisfaction or waiver of customary and other closing conditions.  

Dr. Richard Franklin, M.D., Ph.D., SyntheMed's Executive Chairman, and CEO and President of Pathfinder, commented, "I am pleased at the support shown by SyntheMed's stockholders.  Pathfinder has great potential, and I look forward to closing the merger and beginning a new direction for the Company."

About Pathfinder

Pathfinder is developing a novel cell-based therapy with the potential to revolutionize the treatment of diabetes, renal disease, myocardial infarction, and other diseases characterized by organ-specific cell damage. Leveraging its internal discovery of Pathfinder Cells ("PCs") and a proprietary means of isolating these cells from surrounding tissue, Pathfinder is pioneering a new field in regenerative medicine. PCs are a newly identified mammalian cell type present in very low quantities in a variety of different organs, including the kidney, liver, pancreas, lymph nodes, myometrium, bone marrow and blood.

Early studies indicate that PCs stimulate regeneration of damaged tissues without the cells themselves being incorporated into the new tissue. The cells are "immune privileged", and their effects are independent of the tissue source of PCs. PCs isolated from both rat and human tissue sources have shown efficacy in animal models of diabetes, cardiac ischemia, and renal reperfusion injury.

For more information please visit: www.pathfindercelltherapy.com.

About SyntheMed

SyntheMed is a biomaterials company focused on the development and commercialization of anti-adhesion and drug delivery products, and other surgical implants. The Company's research and development initiatives encompass a broad range of bioresorbable polymeric compositions which blend both hydrophilic and hydrophobic components. For more information about SyntheMed please visit: www.synthemed.com.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements or predictions, including statements regarding the potential closing of the merger and the timing thereof, the characteristics and possible uses of the product candidates of each of Pathfinder and SyntheMed and the potential benefits or value to SyntheMed's stockholders of the merger. Actual results may differ materially from these statements.  For risks associated with the merger and Pathfinder, please see SyntheMed's definitive proxy statement filed with the SEC on July 26, 2011.  For risks associated with SyntheMed's business, please see SyntheMed's Form 10-K filed with the SEC on March 25, 2011.

For more information, please contact:

The Ruth Group
Joshua Drumm (investors) / Victoria Aguiar (media)
(646) 536-7006 / (646) 536-7013
jdrumm@theruthgroup.com / vaguiar@theruthgroup.com

Rick Franklin
Executive Chairmain, SyntheMed, Inc.
President and CEO, Pathfinder Cell Therapy, Inc.
Rick.franklin@pathfindercelltherapy.com


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Scientists at ... line options being tried for mesothelioma may be hampering the research that could lead ... research. Click here to read it now. , The team evaluated 98 ...
(Date:5/24/2016)... ... 2016 , ... Cell therapies for a range of serious ... at Worcester Polytechnic Institute (WPI) that yielded a newly patented method of converting ... novel method, developed by WPI faculty members Raymond Page, PhD, professor of practice ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... The need for blood donations in South ... week by the South Texas Blood & Tissue Center, blood donations are on the decline. ... years, and they are down 21 percent in South Texas in the last four years ...
(Date:5/23/2016)... May 23, 2016 - Leading CRO,s Use ... - Frontage Implement a Single Platform to Manage End-to-end Operations ... Within the Bioanalytical lab Frontage Laboratories, a full-service contract ... and China , has selected IDBS, ... In addition to serving as the global electronic lab notebook (ELN), ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):